AU2001233028A1 - 5-alkylpyrido(2,3-D)pyrimidines tyrosine kinase inhibitors - Google Patents

5-alkylpyrido(2,3-D)pyrimidines tyrosine kinase inhibitors

Info

Publication number
AU2001233028A1
AU2001233028A1 AU2001233028A AU3302801A AU2001233028A1 AU 2001233028 A1 AU2001233028 A1 AU 2001233028A1 AU 2001233028 A AU2001233028 A AU 2001233028A AU 3302801 A AU3302801 A AU 3302801A AU 2001233028 A1 AU2001233028 A1 AU 2001233028A1
Authority
AU
Australia
Prior art keywords
compound
methyl
pyrimidin
pyrido
cyclopentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233028A
Other languages
English (en)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Peter Laurence Toogood
Scott Norman Vanderwel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2001233028A1 publication Critical patent/AU2001233028A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU2001233028A 2000-03-06 2001-01-29 5-alkylpyrido(2,3-D)pyrimidines tyrosine kinase inhibitors Abandoned AU2001233028A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
US60187124 2000-03-06
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2001233028A1 true AU2001233028A1 (en) 2001-10-03

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001233028A Abandoned AU2001233028A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido(2,3-D)pyrimidines tyrosine kinase inhibitors

Country Status (36)

Country Link
EP (1) EP1268476A1 (sk)
JP (1) JP2003528101A (sk)
KR (1) KR20020075805A (sk)
CN (1) CN1422268A (sk)
AP (1) AP2002002643A0 (sk)
AR (1) AR034119A1 (sk)
AU (1) AU2001233028A1 (sk)
BG (1) BG107161A (sk)
BR (1) BR0109056A (sk)
CA (1) CA2401368A1 (sk)
CO (1) CO5280200A1 (sk)
CR (1) CR6736A (sk)
CZ (1) CZ20022929A3 (sk)
DZ (1) DZ3308A1 (sk)
EA (1) EA200200802A1 (sk)
EE (1) EE200200506A (sk)
GT (1) GT200100037A (sk)
HN (1) HN2001000040A (sk)
HR (1) HRP20020798A2 (sk)
HU (1) HUP0300136A2 (sk)
IL (1) IL151480A0 (sk)
IS (1) IS6524A (sk)
MA (1) MA26881A1 (sk)
MX (1) MXPA02008535A (sk)
NO (1) NO20024235L (sk)
NZ (1) NZ520962A (sk)
OA (1) OA12227A (sk)
PA (1) PA8513201A1 (sk)
PE (1) PE20011177A1 (sk)
PL (1) PL358271A1 (sk)
SK (1) SK12472002A3 (sk)
SV (1) SV2001000338A (sk)
TN (1) TNSN01036A1 (sk)
WO (1) WO2001070741A1 (sk)
YU (1) YU66502A (sk)
ZA (1) ZA200207110B (sk)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CA2426654C (en) 2000-10-23 2010-12-21 Smithkline Beecham Corporation 2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds
MXPA03007166A (es) * 2001-02-12 2003-11-18 Hoffmann La Roche Pirido-pirimidinas 6-sustituidas.
WO2002068419A1 (fr) * 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
WO2003062236A1 (en) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
CN1646131A (zh) 2002-04-19 2005-07-27 史密丝克莱恩比彻姆公司 新化合物
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
DE60318089T2 (de) 2002-10-09 2008-12-04 Critical Outcome Technologies, Inc. Protein-tyrosine-kinase-inhibitoren
DE602004021558D1 (de) * 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2005020921A2 (en) * 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
EP1685131B1 (en) 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510770A (ja) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2006076706A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
JP2008535822A (ja) 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
PE20100741A1 (es) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
MX2007012951A (es) 2005-03-25 2008-01-11 Glaxo Group Ltd Procedimiento para preparar derivados de pirido[2,3-d] pirimidin-7-ona y 3,4-dihidropirimidino[4,5-d]pirimidin-2(1h)-ona.
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
NZ594628A (en) * 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
AU2006302148B2 (en) * 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PT2074122E (pt) 2006-09-15 2011-08-24 Pfizer Prod Inc Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008047307A1 (en) * 2006-10-16 2008-04-24 Gpc Biotech Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
BRPI0809998B8 (pt) * 2007-04-03 2021-05-25 Array Biopharma Inc composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
ES2608940T3 (es) * 2007-06-15 2017-04-17 Msd K.K. Derivado de bicicloanilina
US8329695B2 (en) 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2278973B1 (en) * 2008-04-07 2011-11-02 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
WO2010039740A1 (en) 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2486037A4 (en) * 2009-10-09 2013-01-16 Afraxis Inc 8-ETHYL-6- (ARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
US8889696B2 (en) 2009-12-18 2014-11-18 Temple University—Of the Commonwealth System of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
JP5512894B2 (ja) 2010-08-05 2014-06-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション ２−置換−８−アルキル−７−オキソ−７，８−ジヒドロピリド［２，３ｄ］ピリミジン−６−カルボニトリル及びその使用
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
DK2688887T3 (en) 2011-03-23 2015-06-29 Amgen Inc DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
PL2710005T3 (pl) * 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
MX2014010176A (es) * 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
PL3431475T3 (pl) * 2013-02-21 2021-09-13 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
CA2954189A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
GEP20217234B (en) 2016-08-15 2021-03-25 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors
JP7226804B2 (ja) * 2017-03-03 2023-02-21 オークランド ユニサービシズ リミテッド Ｆｇｆｒキナーゼ阻害剤及び医薬用途
KR20200131246A (ko) 2018-02-15 2020-11-23 누베이션 바이오 인크. 키나제 억제제로서의 헤테로시클릭 화합물
US20220024916A1 (en) * 2018-12-07 2022-01-27 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic comipound as cdk-hdac dual pathway inhibitor
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
EP4310084A1 (en) * 2021-03-08 2024-01-24 Jinan University Pyridopyrimidine-based compound and application thereof
CN117720531A (zh) * 2022-09-16 2024-03-19 华东师范大学 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EP0964864B1 (en) * 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
YU73300A (sh) * 1998-05-26 2003-08-29 Warner-Lambert Company Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije

Also Published As

Publication number Publication date
GT200100037A (es) 2002-03-04
EP1268476A1 (en) 2003-01-02
TNSN01036A1 (en) 2005-11-10
PE20011177A1 (es) 2001-11-23
BR0109056A (pt) 2003-06-03
NZ520962A (en) 2003-09-26
HRP20020798A2 (en) 2004-02-29
PA8513201A1 (es) 2003-06-30
ZA200207110B (en) 2003-12-04
OA12227A (en) 2004-03-18
SK12472002A3 (sk) 2003-04-01
YU66502A (sh) 2005-09-19
CO5280200A1 (es) 2003-05-30
DZ3308A1 (fr) 2001-09-27
PL358271A1 (en) 2004-08-09
CZ20022929A3 (cs) 2003-02-12
CR6736A (es) 2004-03-10
EA200200802A1 (ru) 2003-02-27
WO2001070741A1 (en) 2001-09-27
MA26881A1 (fr) 2004-12-20
CA2401368A1 (en) 2001-09-27
AP2002002643A0 (en) 2002-12-31
KR20020075805A (ko) 2002-10-05
BG107161A (en) 2003-06-30
SV2001000338A (es) 2001-11-30
HUP0300136A2 (en) 2003-05-28
NO20024235D0 (no) 2002-09-05
NO20024235L (no) 2002-11-05
JP2003528101A (ja) 2003-09-24
EE200200506A (et) 2004-02-16
AR034119A1 (es) 2004-02-04
MXPA02008535A (es) 2002-12-13
IL151480A0 (en) 2003-04-10
HN2001000040A (es) 2001-09-06
IS6524A (is) 2002-08-23
CN1422268A (zh) 2003-06-04

Similar Documents

Publication Publication Date Title
AU2001233028A1 (en) 5-alkylpyrido(2,3-D)pyrimidines tyrosine kinase inhibitors
USRE47739E1 (en) 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
JP5513558B2 (ja) タンパク質キナーゼ阻害剤としての化合物および組成物
KR101364277B1 (ko) 단백질 키나제 억제제로서의 화합물
AU2003237009A1 (en) 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones
WO2001019825A1 (en) Pteridinones as kinase inhibitors
US20030073668A1 (en) Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
EP1254137A1 (en) PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
TWI464170B (zh) ５-酮基-５，８-二氫吡啶并［２，３-ｄ］嘧啶衍生物，其製備及其治療用途